Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novartis’ Heart Drug Could Save 28,000 US Heart Failure Patients Each Year

XTALKS VITALS NEWS

Heart Failure

According to the researchers in the latest study, if all 2.2 million eligible patients were to use Entresto, the drug could delay or prevent 28,484 deaths, per year.

Share this!

Tweet: Novartis' Entresto could prevent 28,000 #heartfailure deaths in the US each year. http://ctt.ec/bfb8l+Novartis' Entresto could prevent 28,000 heart failure deaths in the US each year.

Tweet: Novartis' Entresto to be more cost-effective compared to the standard of care treatment. http://ctt.ec/sSbm0+Novartis' Entresto to be more cost-effective compared to the standard of care treatment.

June 28, 2016 | by Sarah Massey, M.Sc.

A new study published in the journal, JAMA Cardiology, suggests that Novartis’ Entresto could prevent 28,000 heart failure deaths in the US each year. It’s estimated that 2.7 million patients in the US are affected by a specific type of heart failure – known as heart failure and reduced ejection fraction – and approximately 84 percent of this patient population could be candidates for treatment with Entresto.

An additional study – also published in JAMA Cardiology – found treatment with Entresto to be more cost-effective compared to the standard of care treatment, the angiotensin-converting enzyme (ACE) inhibitor, enalapril. Despite launching the heart drug last year, Novartis has seen slow sales of Entresto. The company hopes that this latest data will help boost Entresto’s market presence.

According to the researchers in the latest study, if all 2.2 million eligible patients were to use Entresto, the drug could delay or prevent 28,484 deaths, per year. Based on the results, the researchers say that putting off treatment with the drug could have “substantial downsides.”



The number of eligible patients was estimated based on the drug’s label restrictions, however the study authors admit that the actual number of ineligible patients could be higher. This, along with the increased costs associated with widespread treatment with Entresto, could change the conclusions reached by the researchers.

An earlier clinical trial sponsored by Novartis, found that Entresto reduced the risk of heart failure-related hospitalizations and death by 20 percent, and lowered overall mortality by 16 percent. Despite initial costs, over a 30-year period, treatment with Entresto has been estimated to be more cost-effective than current treatments.

In an effort to collect further supporting data for the drug, Novartis has expanded their clinical trials of the drug. In the face of increasing generic competition, Novartis is hopeful that the heart drug will help boost revenue.


Keywords: Heart Failure, Heart Drug, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News


PTC to Acquire Marathon’s Recently Approved Duchenne Muscular Dystrophy Drug

March 17, 2017 - Amid a drug pricing controversy, PTC Therapeutics has agreed to buy Marathon Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug, Emflaza.

Featured In: Pharmaceutical News


Memphis Meats Produces World’s First Poultry from Animal Cells

March 17, 2017 - Silicon Valley-based food manufacturing company, Memphis Meats, has produced the world’s first “clean poultry” by growing chicken and duck cells outside the animals.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.